Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Gip and glp-1 double agonist polypeptide compound, pharmaceutically acceptable salt and use

A technology of GLP-1 and peptide compounds, applied in the direction of hormone peptides, organic chemistry, hormone receptors, etc., can solve the problems of prolonging the half-life of peptides, achieve hypoglycemia and slow down weight gain, low production cost, long drug effect time Effect

Active Publication Date: 2021-12-10
HANGZHOU HEALTHYTIDE BIOTECHNOLOGY CO LTD
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the use of fatty acids can improve the half-life of the peptides, applicants discovered that, as part of the present invention, the length, composition and location of the fatty acid chains and the linker between the peptide and the fatty acid chains may have unexpected effects on GIP and GLP-1 agonist activity Balanced effects while prolonging the half-life of the peptide

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Gip and glp-1 double agonist polypeptide compound, pharmaceutically acceptable salt and use
  • Gip and glp-1 double agonist polypeptide compound, pharmaceutically acceptable salt and use
  • Gip and glp-1 double agonist polypeptide compound, pharmaceutically acceptable salt and use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0090] Embodiment 1, the synthesis of SEQ ID NO: 1 polypeptide compound:

[0091] YVEGTFTSDYSIVLDKIAQK(HOOC-(CH 2 ) 16 -CO-γ-Glu-AEEA-AEEA)AFVQWLIAGGPSSGAPPPS-NH 2

[0092] 1. Synthesis of peptide chains

[0093] 1.1 Resin swelling

[0094] Weigh 10g of Fmoc-Rink Amide AM Resin (degree of substitution 0.35mmol / g), swell with 100mL of DCM for 30min, filter to remove DCM, then swell with 100mL of DMF for 30min, rinse with DMF and 100mL of DCM respectively.

[0095] 1.2 Synthesis of Fmoc-Ser(tBu)-Rink Amide AM Resin

[0096]Dissolve Fmoc-Ser(tBu)-OH (8mmol), HOBT (16mmol) and DIC (16mmol) in 100mL of DMF, then add this solution to the resin obtained in the previous step to react for 2 hours, and filter the reaction solution after completion. The resin was washed 3 times with 100 mL each of DCM and DMF.

[0097] 1.3 Removal of Fmoc protecting group

[0098] Add 25% piperidine / DMF (V / V) solution containing 0.1M HOBt to the washed resin to remove Fmoc, and wash the resin 3 t...

Embodiment 2

[0108] Embodiment 2, the synthesis of SEQ ID NO:2 polypeptide compound:

[0109] YXEGTFTSDYSIXLDKIAQK(HOOC-(CH 2 ) 16 -CO-γ-Glu-AEEA-AEEA)AFVQWLIAGGPSSGAPPPS-NH 2

[0110]

[0111] The synthesis method was the same as in Example 1, and the collected solution was freeze-dried to obtain 1.45 g of pure product.

Embodiment 3

[0112] Embodiment 3, the synthesis of SEQ ID NO:3 polypeptide compound:

[0113] YXEGTFTSDYSIXLDKIAQK(HOOC-(CH 2 ) 16 -CO-γ-Glu-AEEA-AEEA)AFVQWLIAGGPSSGAPPPS-NH 2

[0114]

[0115] The synthesis method was the same as in Example 1, and the collected solution was lyophilized to obtain 1.51 g of pure product.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a class of GIP and GLP-1 double agonist polypeptide compound, which belongs to the technical field of polypeptide medicinal chemistry. The amino acid sequence of this type of GIP and GLP‑1 dual agonist polypeptide compound is: YXaa 1 EGTFTSDYSIXaa 2 LDKIAQXaa 3 AFVQWLIAGGPSSGAPPPS, and the C-terminal amino acid of this type of polypeptide compound is amidated as the C-terminal primary amide. The preparation method, pharmaceutically acceptable salt, pharmaceutical composition and medicament of the polypeptide compound of the present invention. The polypeptide compound of the present invention has both hypoglycemic and weight-reducing effects, and can be used as an effective raw material for preparing medicines for treating or preventing diabetes or weight-loss medicines.

Description

technical field [0001] The present invention relates to the field of polypeptide compounds, in particular to a polypeptide compound with double incretin peptide analogues, which stimulates the receptors of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) body, and can be used to treat type 2 diabetes. The present invention also relates to the pharmaceutically acceptable salt of the polypeptide compound, the polypeptide pharmaceutical composition, the preparation method of the medicament and the use thereof. Background technique [0002] The cause of metabolic syndrome is abnormal metabolism of various substances such as protein, fat and carbohydrates. Overnutrition and reduced physical activity can lead to obesity and obesity-related diseases such as diabetes. In recent years, the incidence of type 2 diabetes and abnormal blood lipid metabolism has been increasing; type 2 diabetes is the most common form of diabetes, accounting for abo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K14/00C07K1/06C07K1/04A61K38/16A61P3/04A61P3/10
CPCC07K14/00A61P3/04A61P3/10A61K38/00C07K14/605C07K14/72C07K14/595A61K38/16A61K45/06C07K14/001
Inventor 赵呈青谷海涛施国强姜建军王蔡典
Owner HANGZHOU HEALTHYTIDE BIOTECHNOLOGY CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com